First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi

Effective salvage options inducing high complete metabolic response (CMR) rates without significant toxicity are needed for Hodgkin lymphoma (HL) patients failing induction treatment and who are candidate to autologous stem cell transplantation (ASCT). Brentuximab vedotin (BV) and bendamustine are a...

Descripción completa

Detalles Bibliográficos
Autores principales: Broccoli, A., Argnani, L., Botto, B., Corradini, P., Pinto, A., Re, A., Vitolo, U., Fanti, S., Stefoni, V., Zinzani, P. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906387/
https://www.ncbi.nlm.nih.gov/pubmed/31827067
http://dx.doi.org/10.1038/s41408-019-0265-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906387/
https://www.ncbi.nlm.nih.gov/pubmed/31827067
http://dx.doi.org/10.1038/s41408-019-0265-x

Ejemplares similares